Short Interest in Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) Decreases By 39.3%

Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) saw a significant drop in short interest during the month of June. As of June 15th, there was short interest totaling 191,896 shares, a drop of 39.3% from the May 31st total of 315,885 shares. Currently, 1.1% of the shares of the company are short sold. Based on an average daily volume of 6,417,679 shares, the days-to-cover ratio is presently 0.0 days.

Genenta Science Price Performance

NASDAQ GNTA traded up $0.01 during trading on Thursday, reaching $1.75. The company’s stock had a trading volume of 68,420 shares, compared to its average volume of 1,254,562. The business’s fifty day moving average price is $1.21 and its 200-day moving average price is $1.10. Genenta Science has a twelve month low of $0.55 and a twelve month high of $10.00. The company has a current ratio of 14.16, a quick ratio of 14.16 and a debt-to-equity ratio of 0.35.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised Genenta Science from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, June 24th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Hedge Funds Weigh In On Genenta Science

Several institutional investors have recently added to or reduced their stakes in the stock. Eurizon Capital SGR S.p.A. acquired a new stake in Genenta Science during the 4th quarter worth approximately $536,000. Ghisallo Capital Management LLC acquired a new position in shares of Genenta Science in the fourth quarter valued at approximately $482,000. Weiss Asset Management LP acquired a new position in shares of Genenta Science in the fourth quarter valued at approximately $480,000. Norges Bank purchased a new stake in shares of Genenta Science during the fourth quarter worth approximately $337,000. Finally, Alyeska Investment Group L.P. purchased a new stake in shares of Genenta Science during the fourth quarter worth approximately $328,000. Institutional investors and hedge funds own 15.13% of the company’s stock.

Genenta Science Company Profile

Genenta Science (NASDAQ: GNTA) is a clinical-stage biotechnology company focused on the development of in vivo hematopoietic stem cell (HSC) gene therapies for the treatment of solid tumors. The company’s proprietary platform enables the transplantation of genetically engineered HSCs that home to tumor sites and continuously deliver immunomodulatory agents. By harnessing the patient’s own stem cells, Genenta aims to establish a sustained, localized anti-tumor immune response with the potential to overcome limitations of traditional cytokine or antibody therapies.

Genenta’s lead product candidate, Temferon, consists of autologous HSCs engineered to produce interferon-alpha under the control of a tumor microenvironment–activated promoter.